- Jul 5, 2009
Lower efficacy and inconsistent results in trials of Sinovac in various countries:
See hidden discussions | Win great prizes | Get free support
Prof Malka Gorfine, Hagai Rossman, Prof Eran Segal, and Dr Uri Shalit analysed national data by age and city.
They identified bigger falls in infections and hospitalisations both in the over-60s, who were vaccinated first, and in the cities which vaccinated the largest proportion of their populations earliest.
These relative changes were not seen in earlier lockdowns.
This gives early but encouraging signs the falls can be linked to the vaccine, and not just to current restrictions.
Separately, Israel's second-largest healthcare provider Maccabi published figures showing 66 people out of a group of 248,000 vaccinated (0.03%) caught the Covid-19 virus, more than a week after receiving the second dose of the vaccine.
Of those 66, all had mild symptoms and none were hospitalised.
Unlike the MoH, Maccabi compared the infection rate with 900,000 unvaccinated people with a similar demographic profile. In this group during the same time period, 8,250 caught Covid - 11 times as many.
They estimated this meant the vaccine was 92% effective when used in a population - very similar to the 95% Pfizer found in a controlled clinical trial.
Covid-19 vaccines that use mRNA, such as those made by Pfizer/BioNTech and Moderna, require storage at around -80C. Valor glass can withstand temperatures from between -180C and 400C.
Resistance to extreme heat is useful because pharmaceutical firms wash vials and heat them to around 350C to sterilise them before filling them with products.
Are they reusable? Or at recyclable?Slightly off-topic, but interesting article on the technology behind those fancy glass vials used to package vaccines:
Around 3 in every 1,000 people given the vaccines were affected.
Almost all cases were mild, such as sore arm, tiredness and and 'flu-like' illness.
Severe allergic reactions to the Pfizer/BioNTech vaccine can happen but are very rare - between one and two cases per 100,000 doses administered, experts estimate.
The trials will help scientists work out the smallest amount of coronavirus needed to cause infection, and how the body's immune system reacts to it.
Initially, the study will use the virus that has been circulating in the UK since the pandemic began in March, which is of low risk to healthy adults, to deliberately infect volunteers.
In time, a small numbers of volunteers are likely to be given an approved vaccine and then exposed to the virus, helping scientists to find out the most effective ones.
Truly brave or must be some of the dumbest people on earth.Approval granted for volunteer human challenge trials, which will study the infection process under highly controlled conditions: